How to treat non-tumoral portal vein thrombosis in cirrhosis? Towards the use of direct-acting oral anticoagulants

Nagaoki et al. suggest that edoxaban a direct-acting oral anticoagulant (DOAC) may be more effective than warfarin in case of chronic portal vein thrombosis (PVT) complicating cirrhosis (1). Furthermore, the conclusions of the study are that edoxaban following an initial therapy with danaparoid sodium, is effective to reduce the volume of thrombosis, without significantly increasing the risk of bleeding.